Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 7Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Solid Tumor, Adult 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Bites and Stings 2Turcot syndrome 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Oligoprogressive 1Multiple Myeloma 1Liver Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × Immune Checkpoint Inhibitors × Clear all
NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, Ltd

Phase 2 Unknown
80 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡